SCHEDULE: Adage Capital Management Reports Tango Therapeutics Stake

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 5,600,000 shares, representing 3.44% of Tango Therapeutics, Inc. common stock.

Summary

• Adage Capital Management, L.P. (ACM), along with Robert Atchinson and Phillip Gross, have filed a Schedule 13G, indicating a change in beneficial ownership of Tango Therapeutics, Inc. common stock.
• The reporting persons collectively beneficially own 5,600,000 shares of common stock.
• This ownership stake represents 3.44% of the total outstanding common stock.
• The filing is an amendment (Amendment No. 2) to a previous filing.
• The reporting persons are investment managers and individuals associated with investment management entities.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without disclosing new strategic or financial performance information.

Positives

• The filing indicates that the shares were acquired and are held in the ordinary course of business.
• The reporting persons do not hold the shares for the purpose of changing or influencing control of the issuer.

Risks

• The filing does not contain information about specific risks related to Tango Therapeutics, Inc. itself, but rather pertains to the reporting persons' investment activities.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in publicly traded companies. This filing by Adage Capital Management indicates a notable, but not controlling, investment in Tango Therapeutics, a biotechnology company.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding a significant institutional investor's stake, which may influence market perception and trading activity.

Key Dates

Keywords

Tango Therapeutics, Schedule 13G, Beneficial Ownership, Adage Capital Management, Investment Manager, Securities Exchange Act